FDA urges manufacturers to ‘sell quality’ to fight drug shortages, releasing a report on the potential introduction of a rating system to reward transparency and investments in quality management.
GSK announces it initiated Phase III trials for gepotidacin, the first in a new class of antibiotics, as an potential treatment for urinary tract infection.
Research has discovered that bacteria will open holes in their cell wall under certain conditions, potentially leading to a new drug target or greater potency of existing antibiotics.
Mundipharma signs agreement to progress an antifungal candidate through to commercialization, with the potential for it to become the first approved treatment in 13 years.
Enteris enters a licensing agreement with Cara Therapeutics for the ongoing development of the latter’s drug candidate as it continues clinical trials.
Researchers discover scorpion toxin that triggers pain through a previously unknown pathway, potentially opening up new avenues of investigation for treating chronic pain.
